morpholinoanthracycline mx2 has been researched along with Granulocytic Leukemia, Chronic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujiwara, Y; Kasahara, K; Kubo, S; Niitani, H; Nishio, K; Saijo, N; Sugimoto, Y; Takeda, Y | 1 |
Bungo, M; Fourcade, A; Horichi, N; Kasahara, K; Lampidis, TJ; Nishiyama, M; Sasaki, Y; Sugimoto, Y; Takahashi, T; Tapiero, H | 1 |
2 other study(ies) available for morpholinoanthracycline mx2 and Granulocytic Leukemia, Chronic
Article | Year |
---|---|
Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carubicin; Cell Division; Cell Line; Cell Survival; Doxorubicin; Drug Resistance; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Subcellular Fractions; Tetradecanoylphorbol Acetate | 1991 |
3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.
Topics: Antibiotics, Antineoplastic; Biological Transport; Carubicin; Cell Line; Cell Nucleus; Cell Survival; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Doxorubicin; Drug Resistance; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured | 1990 |